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Abstract
A series of challenge experiments were performed in order to investigate the acute phase responses to foot-and-
mouth disease virus (FMDV) infection in cattle and possible implications for the development of persistently
infected “carriers”. The host response to infection was investigated through measurements of the concentrations of
the acute phase proteins (APPs) serum amyloid A (SAA) and haptoglobin (HP), as well as the bioactivity of type 1
interferon (IFN) in serum of infected animals. Results were based on measurements from a total of 36 infected
animals of which 24 were kept for observational periods exceeding 28 days in order to determine the carrier-status
of individual animals. The systemic host response to FMDV in infected animals was evaluated in comparison to
similar measurements in sera from 6 mock-inoculated control animals.
There was a significant increase in serum concentrations of both APPs and type 1 IFN in infected animals
coinciding with the onset of viremia and clinical disease. The measured parameters declined to baseline levels
within 21 days after inoculation, indicating that there was no systemically measurable inflammatory reaction related
to the carrier state of FMD. There was a statistically significant difference in the HP response between carriers and
non-carriers with a lower response in the animals that subsequently developed into FMDV carriers. It was
concluded that the induction of SAA, HP and type 1 IFN in serum can be used as markers of acute infection by
FMDV in cattle.
Introduction
Foot-and-Mouth-Disease (FMD) is a highly contagious
viral disease which affects cloven-hoofed animals includ-
ing cattle, sheep and pigs, with substantial financial
implications for affected countries. Severity of clinical
disease varies between common domestic species, with
pigs developing severe clinical illness, followed by cattle
showing obvious but less severe clinical signs, whilst the
clinical course of the infection in sheep may be very
mild [1].
Foot-and-mouth disease virus (FMDV) is a positive
stranded RNA virus. It is the prototype virus of the
Aphthovirus genus within the picornavirus family. The
viral genome includes a single large open reading frame
encoding a polyprotein which is cleaved by virus-
encoded proteases giving rise to structural and non-
structural proteins needed for replication and assembly
of new virus particles [2].
The predominant site of initial FMDV replication
within infected animals is thought to be located within
the epithelia of the pharyngeal mucosa [3-6], or alterna-
tively within the lungs [7,8]. From here the virus spreads
via the lymphatics and vascular system to the peripheral
sites of secondary replication, characterized by the pre-
sence of stratified cornified squamous epithelia, such as
the coronary bands and oral cavity [3]. Infected cattle
develop transient viremia lasting for 2-3 days, which is
effectively counteracted by the development of circulat-
ing anti-FMDV antibodies. The clinical disease follows a
rapid time course and is typically manifested by a
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sudden rise in body temperature and development of
vesicular lesions at peripheral areas of viral replication.
Affected animals may display varying degrees of saliva-
tion, inappetence and lameness corresponding to the
severity of lesions. The clinical course of the infection
usually subsides within 7-14 days but the potential
development of persistently infected carrier-animals cre-
ates further complications for disease control. FMDV
carriers are defined as animals with asymptomatic, inter-
mittent, presence of infectious virus in oropharyngeal
fluid more than 28 days post infection (dpi) [9].
It is believed that in these animals (approximately 50%
of infected cattle), FMDV is capable of persisting, at a
low level, within pharyngeal epithelial cells [10,11], or as
intact, but largely quiescent, viral particles within germ-
inal centers in pharyngeal tissues [12]. Since carrier ani-
mals are a potential source of infectious virus, their
presence is unacceptable in areas free of FMD.
Development of the carrier state is unaffected by the
presence of neutralizing antibodies in the circulation.
Thus, both animals that are immunologically naïve at
the time of exposure to FMDV, as well as those with
circulating antibodies due to vaccination or previous
exposure to the virus can become FMDV-carriers,
regardless of pre-occurring clinical disease [9,10,13]. It is
known that FMDV carriers do exhibit a measurable
adaptive immune-response comparable to that of ani-
mals that clear the infection [14] but there is still a sig-
nificant lack of knowledge regarding the innate
immune-response to FMD in cattle. The duration of the
carrier state varies between species, with the longest
duration recorded in African buffaloes (5 years), fol-
lowed by cattle (2 years) and sheep (9 months) [15-18].
Pigs do not become carriers [14].
The innate immune response induced by a viral infec-
tion in the upper respiratory tract is characterized by
initial activation of peripheral primary effector cells
which function to initiate a local inflammatory response,
priming and recruiting activators of the cellular immune
response. Macrophages present in the respiratory tract
produce pro-inflammatory cytokines such as tumor
necrosis factor-a, interleukin-1 and interferon (IFN)
upon stimulation of pattern recognizing surface recep-
tors, causing alterations in local vascular walls, and pro-
viding recruitment and activating stimuli to antigen
presenting cells and phagocytes [19,20].
Type 1 IFNs are also known as viral IFNs and include
interferon-a and -b. These IFNs are secreted by virus
infected cells with the function of blocking spread of
virus to uninfected cells by inducing alterations in gene
transcription and protein synthesis following their inter-
action with common cell-surface interferon receptors
[20,21]. It has been proposed that type 1 IFNs may have
an important role in the host response to FMDV
[14,22,23] and that the ability of the virus to induce an
IFN response may be related to the pathogenicity of dif-
ferent isolates of FMDV [24,25].
Locally produced pro-inflammatory mediators also
cause alterations in hepatic metabolism, inducing the
production of various acute phase proteins (APPs) in
the circulation [19]. APPs have been defined as proteins
for which serum concentrations are significantly altered
in acutely infected animals, compared to that of animals
which are clinically healthy [26]. The proteomic pattern
of the acute phase response varies between animal spe-
cies and also depends upon the pathogen responsible
for inducing the response [27,28].
Previous studies have shown a correlation between
increased serum levels of bovine haptoglobin (HP) and
the onset of clinical disease in bovine respiratory disease
[26], as well as in infections with bovine respiratory syn-
cytial virus [29]. Increased serum concentrations of HP
in cattle acutely infected with FMDV through aerosol
exposure, have also been demonstrated [30].
The production of HP and serum amyloid A (SAA)
are considered reliable indicators of acute inflammation
caused by various infectious agents in cattle [31].
The aim of this study was to investigate the innate
immune response to infection with FMDV in cattle by
measuring systemic levels of acute phase proteins SAA
and HP as well as the biological activity of type 1 IFN in
serum. Results from these measurements were evaluated
in relation to the timing of the appearance of clinical
signs of disease as well as the detection of viremia and
circulating antibodies. Measured parameters were
further analyzed statistically in order to evaluate
whether there was any detectable difference in host
response between the animals that developed into per-
sistently infected carrier animals and those that were
efficient in clearing the infection completely.
Materials and methods
Animal experiments and samples
Animal experiments were performed in high contain-
ment research facilities at DTU-Vet, Lindholm Island,
Denmark, in accordance with the requirements of the
Danish Animal Experiments Inspectorate (License 2003/
561-742; 2008/561-1541).
Three independent experiments were included in this
study. The animals used were 4-5 month old steers of
mixed-Holstein breed. The first experiment (FMD 2008)
was performed with 12 animals (six inoculated and six
in direct contact). In each of the two subsequent experi-
ments (FMD 2010 a + b), three uninfected control ani-
mals, kept in a separate isolation unit, were used in
addition to the twelve test animals. Results from this
study are thus based on measurements in 36 FMDV
infected animals and 6 uninfected controls. Apart from
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observations of clinical signs of disease and measure-
ments of standard para-clinical parameters such as virus
excretion and development of circulating antibodies (see
description of protocol below), all three experiments
included assays for the serum concentrations of the
APPs (SAA and HP) as well as for the bioactivity of
type 1 IFN in serum. In the first experiment (FMD
2008) animals were kept under observation for a total of
100 dpi, whilst the experimental periods for the two
subsequent experiments (FMD 2010 a + b) were 35 and
14 dpi respectively. The following protocol was used in
all three experiments.
All animals were pre-treated using a broad spectrum
antibiotic (enrofloxacin; “Baytril©“; 2.5 mg/kg) for four
days upon arrival in order to reduce the level of any
existing bacterial infection. Animals were subsequently
allowed a period of acclimatization for a minimum of 10
days, and were further treated with b-lactam penicillin
("streptocillin©“; 5 mL/100 kg) for four days around
inoculation to avoid interference caused by any bacterial
infections.
Six animals were inoculated with FMDV O UKG 34/
2001 (original inoculum obtained from the Institute for
Animal Health (IAH)-Pirbright, and then passaged once
in cattle) using subepidermo-lingual injection, each ani-
mal receiving approximately 106.9 TCID50 in a volume
of 0.5 mL administered at 6 to 8 injection sites at the
base of the tongue. A standard protocol for sedation
consisting of intravenous injection of Xylazinhydrochlor-
ide (Rompun© 2%; 1.5 mL/animal) was used for inocula-
tion and the sedation was reversed through intravenous
administration of Antipamezol (Antisedan©; 0.5 mL/ani-
mal). Six other animals were kept in continuous direct
contact with the inoculated animals, with two inoculated
plus two contact animals in each pen and with the
stable facilities allowing direct contact between animals
in separate pens.
All animals were monitored daily, with measurements
of rectal temperature and observation of clinical signs.
Serum samples were collected daily from 3 days prior to
inoculation and throughout the first two weeks of the
experiments and thereafter on a weekly basis throughout
the remaining part of the experiment. Blood samples
were stored at 4°C overnight, before centrifugation and
the sera were subsequently stored at -70°C.
Samples of oropharyngeal fluid (probang samples) [32]
for quantification of virus excretion, in order to define
the carrier status of individual animals [33], were col-
lected prior to inoculation, once daily during the first
week after inoculation, then every other day throughout
the second week and on a weekly basis subsequently.
Probang samples were collected at closer intervals from
post infection day (pid) 28 until termination of the
experiment so that the carrier status of individual ani-
mals was based on the analysis of a minimum of four
samples. Control animals were handled and sampled fol-
lowing a protocol similar to that used for infected ani-
mals. The animals were sedated and “mock-inoculated”
using phosphate buffer, in order to mimic the procedure
used for inoculation and sample collection in the test
groups.
Quantification of Acute Phase Proteins in serum
Serum Amyloid A
Serum concentrations of SAA were determined using a
sandwich-ELISA kit (Tridelta Developments Ltd. May-
nooth, County Kildare, Ireland). Samples were analyzed
at a dilution of 1:500, according to the manufacturer’s
instructions. A standard dilution of the SAA calibrator
included in the kit was added in duplicate to each of the
ELISA plates and SAA concentrations in the sera were
determined from the standard curves.
Haptoglobin
Serum concentrations of HP were determined using a
sandwich-ELISA, following a protocol described in detail
previously [29] using monoclonal anti-bovine haptoglo-
bin antibodies kindly provided by Dr Philip Griebel,
University of Saskatchewan, Canada.
Briefly, microtitre plates were coated with anti-bovine
haptoglobin ascites fluid in carbonate buffer. Serum
samples were tested at three dilutions (1:100; 1:300;
1:900), together with a calibration standard of acute
phase serum with known concentrations of HP. Bound
antigen was detected using biotinylated anti-bovine hap-
toglobin Mabs, by staining with TMB reagent in citrate
buffer. The colour development was terminated by addi-
tion of sulfuric acid, and OD-values were read using a
standard ELISA reader at wavelengths of 450/650 nm.
Quantification of the bioactivity of Type 1 IFN in serum
Biological activity of type 1 IFN was quantified with an
Mx/CAT reporter gene assay [34], using the transfected
MDBK-t2 cell line kindly provided by Dr Bryan Charles-
ton (IAH-Compton, UK). Briefly, the cells were seeded
in 24-well plates and cultured in 1500 μL of medium
(EMEM with blasticidin (10 μg/mL), penicillin (100 IU/
mL), streptomycin (100 μg/mL) and 10% FCS).
Serum samples, diluted 1:5 in cell culture medium
containing 2% FCS, were added to the cells and incu-
bated overnight at 37°C. All samples were tested in
duplicate, in parallel with standard concentrations
(0.125 to 90 IU/mL) of recombinant human IFN-a
(Invitrogen). Cells were harvested and CAT-expression
was quantified using a commercial CAT-ELISA kit
(Roche Applied Science) following the manufacturer’s
instructions.
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Quantification of anti-FMDV antibodies using a solid
phase blocking ELISA
Serum concentrations of FMD specific antibodies were
measured using a serotype-specific solid phase blocking
ELISA [35]. In brief, microtitre plates were coated with
guinea-pig immune sera raised against FMDV O Man-
issa before addition of inactivated FMDV antigen. Sam-
ples of the bovine sera were then added, incubated
overnight and then rabbit anti-FMDV serotype O serum
was added and the bound antibodies were detected
using horseradish-peroxidase conjugated porcine anti-
rabbit IgG. All serum samples were initially screened at
a dilution of 1:5 and positive samples (blocking percen-
tage >50%) were analyzed in a two-fold titration starting
at a dilution of 1:10 to allow determination of antibody
titers.
Quantification of viremia and excretion of FMDV RNA in
probang samples
Quantification of FMDV RNA in serum and probang
samples was performed using quantitative RT-PCR [33].
Total RNA was extracted using a MagNa Pure LC Total
Nucleic Acid Isolation Kit (Roche) with an automated
robotic workstation (Roche) from 200 μL of sample,
according to the manufacturer’s instructions. Each RNA
sample was eluted in a volume of 50 μL and stored at
-70°C until further processing. Reverse transcription of
FMDV RNA was carried out using 6 μL of extracted
RNA in a total volume of 15 μL, using a TaqMan RT
kit with random hexamer primers (Applied Biosystems)
at 48°C for 45 min and 95°C for 5 min. Then 7 μL of
each cDNA was mixed with 18 μL of 2x TaqMan uni-
versal PCR mastermix (Applied Biosystems) containing
22.5 pmol of each primer and 5 pmol of fluorescently
labeled probe. PCR amplification was carried out for 50
cycles, in an Applied Biosystems Model Mx 3005P
Thermal cycler and analysed using MxPro qPCR
software.
Statistics
APP responses were log-transformed in order to reduce
fluctuations in data and to ensure a normal distribution
of residuals. A response measure representing the area
under the curve was constructed, where linear interpola-
tion between points of observations was used, and a
slight extension at end points to put equal weight on
observations evenly spaced in time. APP responses were
analyzed with a standard random effects model [36],
where the identification of the three sequentially per-
formed experiments ("survey”) was entered as a random
effect. Fixed effects were Carrier status ("Carrier”), route
of infection ("status": inoculated, contact or control),
level of viremia and maximum anti-FMDV antibody
titre. The effect of the carrier-status of individual
animals was modeled as a covariate with the values 1/0
representing carrier/non-carrier. Tests were performed
as likelihood ratio tests, according to the following
model,
log(AUCij) =βAlog(Antibodies)ij + βVViremiaij + βCCarrierij+
βStatus.ij + ηYSurvey.i + εij,i = 1 : 3, j = 1 : ni,
where b represents coefficients of effect and h repre-
sents the standard deviation between experiments (i).
Model control was performed with standard techni-
ques [36]. For the APP SAA, the model control revealed
that criteria were not met for the response measure, and
the tests were subsequently performed as z-tests (con-
tinuous fixed effects). All analyses were performed with
Splus© software version 6.1 (Insightful Corp. 2002).
Results
Clinical symptoms
All animals included in the test groups developed mild
to moderate clinical signs of FMD, with an increase in
body temperature (Figure 1a) and vesicular lesions in
the oral cavity being the most prominent findings occur-
ring in all individuals. Less than half of the animals
developed vesicular lesions on the feet and only one
individual (out of 36) developed clearly visible lameness.
Inoculated animals developed clinical signs of FMD at
pid 1-2, whilst onset of clinical disease in contact ani-
mals was observed from pid 2-5. The animals showed
no loss in appetite and all animals recovered from clini-
cal disease within approximately seven days, without
further complications, and without the need of suppor-
tive medical treatment.
Viremia and development of antibodies
FMDV RNA was detectable in serum from all infected
animals for a period of four to seven days (Figure 1b).
Inoculated animals showed significant viremia at pid 1,
reflecting the very rapid replication and systemic spread
of FMDV. Anti-FMDV serotype O antibodies in serum
reached the diagnostic cut-off level, defined as a block-
ing percentage of 50%, at around pid 4 to 5 in inocu-
lated animals and at pid 7 to 9 in the contact group
(Figure 1c). Appearance of circulating antibodies was
accompanied by a rapid reduction in viremia. There
were no detectable differences in the level of viremia
(presented as the number of copies of FMDV genome
per μL of serum) or the anti-FMDV O antibody titres
(data not shown) between directly inoculated and con-
tact infected animals, or between carriers and non-
carriers.
Prevalence of Carriers
Carrier status was determined on the basis of detection of
FMDV RNA, using qRT-PCR, in probang samples
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beyond 28 dpi [33]. An animal was regarded as being a
carrier following detection of at least two positive pro-
bang samples (Ct value <40) out of a minimum of four
samples collected beyond pid 28. Detailed information
on the extent of virus excretion in probang samples in
carriers and non-carriers has been included in a separate
report (Stenfeldt and Belsham, submitted). In summary,
animals identified as FMDV carriers had detectable levels
of FMDV RNA (Ct <40) in probang samples harvested
throughout the entire length of the experimental period
whereas FMDV RNA became undetectable in probang
samples from the non-carriers by approximately 14 dpi.
One of the experiments (FMD 2010b) was terminated at
14 dpi, for technical reasons, and so it was therefore not
possible to determine carrier-status in this experiment.
In the remaining two experiments (FMD 2008 and FMD
2010a) the prevalence of carriers was 6/12 (50%) and 3/
12 (25%) respectively (see Table 1), consistent with what
has been found previously in experimental infections
with FMDV [1,17,37].
Acute phase proteins
The serum levels of APPs showed a consistently occur-
ring peak, coinciding with the onset of clinical symptoms
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Figure 1 Characterization of clinical signs and acute phase responses in FMDV-infected cattle. The results shown are the mean values
(+/- S.E.M) for the indicated parameters from three separate experiments each including 12 or 15 cattle (6 inoculated with FMDV, 6 in-contact
and 3 uninfected controls in 2 of the experiments). a) Temperature and timing of occurrence of characteristic vesicular lesions within the oral
cavity. b) Viremia measured by qRT-PCR expressed as copies of FMDV genome/μL of serum c) anti-FMDV (type O) antibodies in serum expressed
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f) Serum Amyloid A in serum (μg/mL).
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(Figure 1e-f). Directly inoculated and contact animals
showed similar responses when the areas under the curve
(AUC) were compared for the serum concentrations of
SAA during the observation period of 14 days after infec-
tion. For the HP-response, there was however, a small
but statistically significant difference (p = 0.04) between
inoculated and contact animals, with a larger response in
the directly inoculated animals. There was a very marked
and statistically significant (p < 0.0001) difference in the
AUC values for both SAA and HP when comparing test-
groups (FMDV inoculated and contacts) to the unin-
fected control animals.
It is interesting to note that, there was also a statisti-
cally significant difference (P = 0.015) in the AUC values
for the serum concentration of HP between the animals
that became carriers and the non-carriers, with lower
values in the carrier animals (Figure 2f; Tables 2 and 3).
The difference in the HP-response between carriers and
Table 1 Distribution of FMDV carriers within the directly
inoculated and contact infected animals.
Experiment
ID
Number of animals
(Inoculated:
Contact)
Carriers
(Inoculated:
Contact)
Non-Carriers
(Inoculated:
Contact)
FMD 2008 12 (6:6) 6 (4:2) 6 (2:4)
FMD 2010 a 12 (6:6) 3 (1:2) 9 (5:4)
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Figure 2 Comparison of acute phase protein and IFN measurements in carrier and non-carrier cattle on linear (a-c) and logarithmic
scale (d-f). a+d) Bioactivity of type 1 IFN in serum (iu/mL). b+e) Serum amyloid A in serum (μg/mL). c+f) Haptoglobin in serum (μg/mL).
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non-carriers was unrelated to, and could therefore not
be explained by, the observed difference between inocu-
lated and contact-infected animals for this parameter.
There was no difference in the AUC values for serum
concentration of SAA between carriers and non-carriers
(Table 2).
Type 1 IFN
Type 1 IFN bioactivity, as measured by the activation of
the Mx promoter in the MDBK-t2 cells, showed a reac-
tion pattern similar to the APPs, with a marked peak at
the onset of clinical symptoms and thus significant dif-
ferences in response between the infected test-groups
and uninfected control animals. Contact animals seemed
to show slightly lower peaks in IFN response than
directly inoculated animals (Figure 1d), although this
difference was not statistically significant (Table 2).
There was no difference in the AUC values for the type
1 IFN bioactivity between carriers and non-carriers
(Table 2).
Discussion
The observed progression of the clinical infection,
including the level of viremia and titres of circulating
antibodies, was similar to what has been described pre-
viously for infection with FMDV O UKG/34 2001 in
cattle [38,39].
Measurements of serum concentrations of the APPs,
SAA and HP, indicated a rapid acute phase response
which coincided with the appearance of clinical signs of
disease. It has previously been proposed that the sensi-
tivity of SAA as a marker of infection could be higher
than that of HP [31]. In our studies we observed a rela-
tively high basal level and measurable changes in the
level of SAA in some of the mock-inoculated control
animals, although by no means approaching the signifi-
cantly up-regulated concentrations observed in animals
infected with FMDV. In contrast to this, we recorded
very low basal levels in the HP measurements within
uninfected animals, whilst both APP markers showed a
clear response with significantly increased concentra-
tions within the sera from infected animals. It has been
shown that changes in SAA levels are more easily
induced by physical stress than for HP [40]. It may be
that the procedures used for handling of animals for
sampling, including the protocol for sedation used for
inoculation, could be responsible for inducing a signifi-
cant stress response in the animals, which might be the
cause of the observed SAA response in some of the
mock-inoculated control animals.
The acute phase response to FMD in cattle has pre-
viously been investigated by Hofner et al. [30] using
measurements of HP in sera from cattle that were
infected with FMDV O BFS 1860 following aerosol
exposure. It was reported that an increase in serum con-
centrations of HP occurred 8-9 days after virus exposure
and 1-3 days after the onset of viremia and appearance
of clinical signs. It was concluded that there was no
measurable rise in HP during the “pre-viremic” phase of
FMD infection. Furthermore, it was proposed that this
finding was indicative of little or no tissue damage dur-
ing initial replication of FMDV in the pharyngeal
epithelia.
The clinical course of FMD in our experiments dif-
fered slightly from what was described by Hofner et al.
[30]. We observed a more rapid course of infection,
with simultaneous appearance of viremia and clinical
signs of disease, including an increase in body tempera-
ture, in both directly inoculated and in contact animals.
We also detected an increase in serum concentrations
of HP as well as SAA, which for the majority of the
Table 2 Summary of P-values for comparisons of the AUC
values of serum concentrations of APPs and IFN during a
test period of 14 dpi.
Inoculated and
Contacts vs.
Controls
Inoculated vs.
Contacts
Carriers vs.
Non-Carriers
SAA <0.0001*** 0.61 0.49
IFN <0.0001*** 0.43 0.27
Haptoglobin <0.0001*** 0.04* 0.015*
Levels of significance: ***= p < 0.0001; **= p < 0.001 *= p < 0.05.
Table 3 Coefficients of effect (b) for contribution to AUC values of serum HP of individual animals for statistically
significant effects: carrier-status ("Carrier": carrier (1)/non-carrier (0)), route of infection ("Status": inoculated/contact-
infected (uninfected controls are not included in this analysis as these do not become carriers))
Final model log(Hpij) = bC Carrierij + bStatusij +hYSurveyi + εij, i = 1:3,j = 1:ni,
bC 95% confidence interval
Carrier Status Carrier -1.14 -1.98 to -0.3
Non-carrier 0 (NA)
bStatus 95% confidence interval
Route of infection Inoculated 4.52 3.19 to 5.85
Contact 3.65 2.34 to 4.96
h represents standard deviation between experiments (i).
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animals began at the same time as the observed onset of
clinical disease and appearance of viremia. Thus, there
was no apparent lag phase between the rise in body
temperature and the measurable acute phase response
in serum.
The differences in clinical observations may partly be
a result of the different means of inoculation used in
the two studies; direct inoculation in our studies versus
aerosol exposure in the study performed by Hofner et
al. [30]. However, in our studies, we also saw similar
timing of reactions in animals infected by contact expo-
sure as in those that had been directly inoculated with
simultaneous detection of viremia and clinical para-
meters. Thus, the observed variations in results are
more likely to be derived from differences in sensitivity
of the different assays used for quantification of HP and
detection of viremia in the two studies. In the earlier
study, the HP concentration was quantified through an
assay measuring hemoglobin binding capacity while vire-
mia was detected by inoculation of primary cell cultures,
whereas we measured HP with a specific and sensitive
ELISA assay and viremia with a quantitative RT-PCR.
The measured changes in the bioactivity of type 1 IFN
in serum followed a similar pattern to what was
recorded for the APPs, with measurable peaks in activity
of IFN in the sera at the onset of clinical disease. There
seemed to be a slight, although not statistically signifi-
cant, difference in maximum peak levels of IFN bioactiv-
ity in inoculated versus contact animals. Animals in the
contact groups acquired the infection through continu-
ous exposure to virus excreted by infected animals,
whereas the inoculated animals received a single high
level dose of virus in the tongue. The different level and
route of virus access to the primary site of replication is
likely to cause a variation in the timing and synchroni-
zation of the initial cellular immune response responsi-
ble for the measured cytokine response.
It is believed that the acute phase response of the liver
is induced in response to the presence of inflammatory
cytokines in the circulation [19]. Our results indicate
near simultaneous timing for the onset of induction of
APPs and type 1 IFN in both inoculated and contact-
infected animals, with the rate of the initial response in
SAA slightly exceeding that of HP. It is possible that the
very rapid onset of viremia, with high levels of virus in
the blood seen as early as pid 1 in the inoculated ani-
mals, could in some way influence the hepatic APP
response in a more direct manner.
Type 1 IFN is produced by virus-infected cells, as well
as by inflammatory cells (macrophages and cells of the
dendritic cell lineage) present within the circulation and
peripheral tissues [41,42]. Previous studies have shown
an up-regulation of IFN-a and-b mRNAs within epithe-
lial cells harvested from FMDV lesions of the oral cavity
[42]. We have attempted to quantify IFN bioactivity in
samples of oropharyngeal scrapings (probang samples)
without any success (data not shown), possibly indicat-
ing that the activity of IFN is somehow inhibited in this
type of sample.
Recent studies in cell culture have demonstrated that
the leader protease (Lpro) of FMDV is capable of down-
regulation of transcription of IFN-b through interaction
with NFB [25,43]. The Lpro also inhibits host cell pro-
tein synthesis [44,45], thus within FMDV-infected cells
the expression of IFN mRNA and its translation should
be blocked. This may suggest that the IFN present in
serum is not produced by cells that are actually infected
with FMDV but by populations of immune cells that
react upon the presence of virus through activation of
pattern recognizing receptors. Plasmacytoid dendritic
cells, also referred to as natural interferon producing
cells (NIPC), are known to produce high levels of type I
IFN in response to virus infection [46]. It is, however,
suggested that it is necessary for non-enveloped viruses
such as FMDV to be in a complex bound by antibody in
order to induce IFN production by cells of this lineage
[47]. This putative relationship does not match the tim-
ing of events observed in our study as the increase in
type 1 IFN activity in serum was detected very early (pid
1-2) which significantly precedes the rise in circulating
anti FMDV-antibody. Investigations of the cellular
source of the systemically measurable rise in IFN activity
might help to further elucidate the interactions between
the virus and the immune response of the host. Previous
studies have reported an increase in IFN-a mRNA levels
in nasal associated lymphoid tissue harvested from the
pharyngeal region of calves acutely infected with FMDV
serotype O [48]. The same study also reported a differ-
ence in the expression of tumor necrosis factor-a (TNF-
a) between carriers and non-carriers in similar samples
collected from a total of six animals at 62 dpi. We have
been unable to find evidence of an up-regulation of IFN
mRNA levels in samples of pharyngeal mucosa collected
at sequential time points during infection. However, we
did corroborate the previous report of a difference in
TNF-a mRNA expression in the pharyngeal epithelium
of FMDV-carriers and non-carriers during the late
phase of infection (> pid 28) (Stenfeldt et al., submitted).
Alsemgeest et al. [49] compared serum concentrations
of SAA and HP in acute and chronic inflammation in
cattle. It was found that the HP/SAA ratio differed dur-
ing different stages of infection, with the serum concen-
tration of SAA exceeding that of HP in acute
inflammation and the opposite occurring during chronic
inflammation. In our studies, we saw that concentrations
of both SAA and HP declined to baseline-levels by pid
14-21, regardless of whether the animal was persistently
infected with FMDV or not. These findings indicate that
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the carrier status in FMDV infection in cattle is not
accompanied by a state of systemically measurable
chronic inflammation.
There was no measurable difference in the serum
reactions of SAA and type 1 IFN between infected ani-
mals which became carriers or non-carriers. For HP,
however, there was a statistical difference in the AUC
values between animals which were identified subse-
quently as carriers and non-carriers with a lower HP
level in carriers. The observed difference in the HP
response is most clearly visible at the latter part of the
timescale when viewing the log-transformed data (Figure
2f). This data may be an indication of slightly prolonged
reaction in HP in the sera of the animals that were suc-
cessful in clearing the infection completely. When
extending the observational period to include analysis of
sera collected at pid 21 it was, however, clear that the
serum concentration of HP did decline to baseline levels
(below the assay detection limit) in all animals regard-
less of carrier-status.
The observed difference in HP-response between
directly inoculated and contact infected animals, which
only just reached statistical significance (p = 0.04), could
possibly (as previously discussed for the IFN-response),
be explained by the differences in the routes and timing
of virus exposure.
The relationship between the HP response and the
development of FMDV carrier animals should be further
investigated in future experiments to elucidate the nat-
ure of the apparent difference in the acute host response
to FMDV between carriers and non-carriers.
There might also seem to be a slight difference in the
time course of SAA and HP responses between animals
which became carriers and non-carriers, with a more
rapid pattern of reactions in the carrier-group. This
apparent difference is, however, most likely caused by a
variation in the timing of the reactions between inocu-
lated and contact animals, with a relatively larger num-
ber of inoculated animals, compared to contact-infected
animals within the group of carriers. However, the route
of infection (directly inoculated versus contact-infected)
did not have any effect on whether the animal devel-
oped into a persistently infected carrier or not (Table 1).
Observations from our experiments indicate that com-
bined measurements of serum concentrations of SAA
and HP can be used as markers of an acute systemic
response to FMDV infection in cattle. This could, for
example, be of value during vaccine studies or transmis-
sion experiments with FMDV isolates of low virulence,
where it would be of interest to detect any systemic
immune response in animals exposed to the virus. Stu-
dies comparing the patterns of the systemic acute phase
response in experiments with FMDV isolates of varying
virulence have been initiated. Preliminary results
indicate a close relationship between the timing and
magnitude of the serum APP response with the severity
of clinical disease, providing an objective tool for valida-
tion of severity of infection.
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